There are 15,361 results relating to "Medicin Viagra-m"
Order by
|
SPICe briefings
Date published:
30 January 2018
Leaving the EU - Implications for Health and Social Care - Data Protection
Potential issues arising from Brexit include regulation of life sciences research and pharmaceutical trials which rely on the UK being compliant with EU Data Protection legislation, particularly with reference to research in genomic medicine and rare disease research. The European Reference Network (ERN) consists of clinicians and other healthcare professio...
Questions and Answers
Date answered:
4 March 2019
S5W-21702
To ask the Scottish Government how many people have been treated with Duodopa since it was approved for use by the Scottish Medicines Consortium (SMC) in June 2016.
Questions and Answers
Date answered:
20 February 2019
S5O-02892
Medical prescribers are also required to follow the prescribing and managing medicines and devices guidelines set out in the General Medical Council’s Good Medical Practice standards which emphasizes safe prescribing.
Questions and Answers
Date answered:
6 November 2018
S5W-19708
To ask the Scottish Government what guidance will be issued to doctors to ensure safe prescription of medicinal cannabis, and when it will be published.
Questions and Answers
Date answered:
8 February 2018
S5W-14280
To ask the Scottish Government when it will publish the findings of its comparative review of the health technology assessment processes of other countries, including those for orphan and ultra-orphan medicines. I refer the member to the answer to question S5W-14278 on 8 February 2018.
Questions and Answers
Date answered:
20 December 2017
S5W-13369
BioMarin have been involved in communications with the Scottish Medicines Consortium (SMC) and any decision over whether or not to make a submission to the SMC is purely one for BioMarin.
Questions and Answers
Date answered:
2 August 2017
S5W-10202
To ask the Scottish Government when the multi-agency taskforce or equivalent group to help introduce new medicines, such as Orkambi for cystic fibrosis, will be established.
Questions and Answers
Date answered:
25 January 2017
S5W-05881
NHS boards are expected to have a clear policy in place to deal with situations which may result in a patient requesting combined NHS and private healthcare including a medicine which is not available in the NHS as set out in the guidance published in CMO letter 2009/03.
Questions and Answers
Date answered:
24 November 2016
S5W-04697
To ask the Scottish Government what assessment it has made of the Scottish Medicines Consortium's decision not to recommend nivolumab for use by patients with advanced renal cell carcinoma.
Questions and Answers
Date answered:
21 June 2016
S5W-00509
This information is published by Information Services Division Scotland and can be found via the ISD website link below: http://www.isdscotland.org/Health-Topics/Prescribing-and-Medicines/Publications/data-tables.asp?id=1495#1495.
